Rapport Therapeutics, Inc. Common Stock Price & Performance (RAPP)

Recent insider transactions at Rapport Therapeutics reveal bullish sentiment among executives. CFO Troy Ignelzi acquired 10,000 shares worth approximately $100,988, while Director Wendy Young purchased 6,000 shares for $61,249. These investments come as the company advances its RAP-219 clinical trials, aiming to address neurological conditions like epilepsy and bipolar mania.123

Rapport Therapeutics has appointed Dr. Jeffrey Sevigny as Chief Medical Officer, bringing extensive expertise in neuroscience drug development. This move aligns with the company’s focus on advancing RAP-219, a potential treatment for epilepsy and bipolar mania. The company’s robust cash reserves are expected to fund operations through 2026.245

The New York State Common Retirement Fund recently acquired a new stake in Rapport Therapeutics, adding to insider purchases by executives. These developments come as the company progresses its Phase 2a trials for RAP-219, with promising data expected later this year. Rapport’s focus on CNS disorders continues to attract attention.647